Clinton Snow
Director/Board Member at ICETANA LIMITED
Clinton Snow active positions
Companies | Position | Start | End |
---|---|---|---|
ICETANA LIMITED | Director/Board Member | 08/02/2022 | - |
DIMERIX LIMITED | Director/Board Member | 01/05/2023 | - |
PolyActiva Pty Ltd.
PolyActiva Pty Ltd. BiotechnologyHealth Technology PolyActiva Pty Ltd. develops drug-polymer conjugate technology. Its platform technology is used to make plastic components for medical devices from drugs and manufacture process is novel and provides greater flexibility over the composition of the final material and better product outcomes compared with competitor technologies. The firm has built drug-polymer conjugates from a number of drug candidates with different chemical structures and linkage points, demonstrating the plasticity of the technology and developed a number of functional co-monomers and polymer segments, which modularises the production of the final conjugate. The company was founded in February 2010 and is headquartered in Melbourne, Australia. | Director/Board Member | - | - |
Career history of Clinton Snow
Training of Clinton Snow
University of Melbourne | Undergraduate Degree |
Statistics
International
Australia | 5 |
Operational
Director/Board Member | 3 |
Undergraduate Degree | 1 |
Sectoral
Health Technology | 3 |
Technology Services | 2 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
ICETANA LIMITED | Technology Services |
DIMERIX LIMITED | Health Technology |
Private companies | 1 |
---|---|
PolyActiva Pty Ltd.
PolyActiva Pty Ltd. BiotechnologyHealth Technology PolyActiva Pty Ltd. develops drug-polymer conjugate technology. Its platform technology is used to make plastic components for medical devices from drugs and manufacture process is novel and provides greater flexibility over the composition of the final material and better product outcomes compared with competitor technologies. The firm has built drug-polymer conjugates from a number of drug candidates with different chemical structures and linkage points, demonstrating the plasticity of the technology and developed a number of functional co-monomers and polymer segments, which modularises the production of the final conjugate. The company was founded in February 2010 and is headquartered in Melbourne, Australia. | Health Technology |
- Stock Market
- Insiders
- Clinton Snow
- Experience